GlucoModicum: EIC Accelerator Push for a Needle-Free Glucose Monitor

Continuous glucose monitors have transformed diabetes care, but every one on the market still works through a filament inserted under the skin. GlucoModicum, a Helsinki company founded in 2018, wants to remove the needle altogether. Its device uses magnetohydrodynamics, a combination of a weak current and a magnetic field, to draw a tiny sample of interstitial fluid to the skin's surface, where a disposable sensor measures its glucose.

In 2021 the European Innovation Council contributed €2.5 million to a €6.57 million project to optimise the device and prove it clinically. The clinical programme has grown to more than 2,000 participants. The product, renamed Sofio, was unveiled in December 2025. It is still waiting for the CE mark it needs to be sold in Europe.

Where GlucoModicum Stands Today

On 18 December 2025 GlucoModicum unveiled Sofio, the renamed Talisman, reporting a mean absolute relative difference (MARD) of 11.5% from studies with more than 2,000 participants. MARD measures how far a monitor's readings stray from reference values; lower is better. The company said the device was progressing through European regulatory processes, that it would launch in Europe first, and that regulatory and commercial updates, including plans for the US, would follow in 2026.

The industrial side has been prepared in parallel. GlucoModicum partnered with the contract manufacturer Phillips-Medisize on the device and with the automation maker Mpac Lambert on sensor production. In June 2024 it said it planned an initial capacity of 100,000 devices a year, with blueprints for up to a million. In February 2026 its investor LocalTapiola wrote that Sofio "has not been approved by authorities yet", that it was "approaching the so-called design freeze phase", and that the next step is a pivotal clinical trial, "a key part of the CE-marking" process. The company then had more than 60 staff and, according to its chief executive, "aims to raise more capital".

The Technology: Pulling Fluid Instead of Piercing Skin

Today's continuous monitors place a thin sensor filament a few millimetres into the skin, where it bathes in interstitial fluid, the liquid between cells whose glucose level tracks the blood's. GlucoModicum's system reverses the direction. According to the EU's project summary, its magnetohydrodynamic transport moves interstitial fluid to the skin surface, where a daily disposable biosensor reacts to the glucose. A reusable transmitter lasts two years and connects to a phone app. The chemistry, glucose oxidase, is the same used in conventional meters; the novelty is the sampling.

The accuracy figure is what will decide the product's fate, and it comes from the company's own studies. No regulator has yet assessed it.

What the EIC Project Promised, and What CORDIS Shows

PREVENTDIABETES ran from 1 February 2022 to 31 January 2024 under the 2021 Open call. Its aim was to optimise the technology and prove it clinically on a wider scale. The EU's June 2024 results summary reports the "single biggest achievement" as "high correlation to blood glucose values in a broad clinical pilot study" and says commercial availability was expected within 12 to 15 months. The project's final report gives the figures behind the earliest test: "10 glucose tolerance tests on 5 healthy volunteers", with a MARD of 12.9% after calibration. It cites two peer-reviewed papers from 2022 on the sampling method and says "we have reached the desired outcomes of the PREVENTDIABETES project".

1. A working needle-free CGMDeliveredDevice and daily biosensor developed; product unveiled as Sofio in December 2025.
2. Clinical proof on a wide scaleReportedMore than 2,000 participants and an 11.5% MARD, company-reported; the peer-reviewed data cover 5 volunteers.
3. Market launch in 2025MissedThe 12-to-15-month window from June 2024 has passed without CE marking or sales.
4. High-volume manufacturingIn progressManufacturing partners named; pilot production was planned for late 2024 and 2025.

What Has Happened Since the Award

The Money

GlucoModicum is a pre-revenue medtech company paying for a large clinical and industrial programme. The filed accounts, reported by Finder and, for 2023 and 2024, by Asiakastieto, show the operating loss rising from €1.93 million in 2021 to €4.99 million in 2024, while the equity ratio fell from 68% to 52% between 2023 and 2024. Headcount rose from 23 to 41.

Why Europe Should Care

The project objective on CORDIS puts the stakes plainly: 6% of the world's population lives with diabetes and another 35% is at high risk. Monitoring that does not hurt could change how many of those people track their glucose, including those who are not yet diabetic. A European company with a genuinely different sampling technology, European manufacturing partners and a Europe-first launch plan is the kind of health technology the EIC was set up to back.

The Verdict

GlucoModicum has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.